A case-control study of over 180,000 men found that men with testicular cancer have a higher incidence of prostate cancer compared to those without a history of the disease. The study revealed a significant increase in aggressive prostate cancers among men with testicular cancer.
A retrospective analysis of 87,500 men treated for prostate cancer found a notable increase in intermediate- and high-risk cases between 2011 and 2013. This trend could lead to 1,400 additional prostate cancer deaths per year if confirmed through further research.
A small prospective study found no significant difference in treatment outcomes between patients with AR-V7-positive and -negative metastatic castration-resistant prostate cancer who received taxane chemotherapy. PSA responses were achieved in 41% of both groups.
The American Society of Clinical Oncology (ASCO) announces its cancer Advance of the Year, four new treatments improving outlook for patients with chronic lymphocytic leukemia (CLL). New therapies include immunotherapy drugs and molecularly targeted drugs offering more effective treatment options.
A pooled analysis of five cohort studies found that smoking before first cancer diagnosis increases risk of developing a second smoking-related cancer. Smoking survivors have up to a 5-fold higher risk of developing a second primary smoking-associated cancer compared to non-smokers.
A large cohort analysis found a significant link between male pattern baldness and aggressive prostate cancer. Men with specific hair loss patterns at age 45 were at a 40% increased risk of developing aggressive prostate cancer. The study supports earlier research suggesting a biological link between baldness and prostate cancer.
Key studies explored preventive mastectomy, compliance with recommended screening mammography, and risk of recurrence after pre-surgery therapy. The symposium featured insights into patient decision-making and post-treatment risks, aiming to enhance treatment approaches and patient care.
Researchers have made significant strides in developing innovative immunotherapies that activate the body's immune response to fight cancer. The new treatments show high activity against advanced melanoma and demonstrate substantial decrease in melanoma recurrence risk.
Four phase III trials released findings on new chemotherapy regimens and targeted treatments for advanced cancers. The studies confirm the effectiveness of commonly used treatments and provide insights into optimal patient care.
Research identifies new ways to ease cancer therapy effects and enhance patient well-being, from fertility preservation techniques to earlier palliative care. Studies show improved survival rates and reduced side effects for certain treatments.
Researchers presented promising results from four clinical trials featuring new targeted drugs for advanced ovarian, lung and thyroid cancers, as well as chronic lymphocytic leukemia. These treatments showed potential to slow disease progression and improve survival rates for patients with relapses or treatment resistance.
A large international study found that women with BRCA1 mutations who underwent preventive ovarian surgery before age 35 had a 77% reduction in total mortality risk. In contrast, women with BRCA2 mutations may delay this procedure until their 40s.
Research advances demonstrate progress in cancer fight, but also stress need for increased funding to translate research into effective treatments. The report highlights three areas of progress: genomics, treatment-resistant cancers, and targeted immunotherapy.
A large prospective study found that patients with a body mass index in the obese range live on average two to three months less after a pancreatic cancer diagnosis compared to healthy-weight patients. Obesity is associated with poorer pancreatic cancer survival rates, even after adjusting for age and disease stage.
A large study found that married cancer patients live markedly longer and are more likely to receive appropriate therapy compared to unmarried patients. Social support from spouses plays a critical role in improving outcomes for these patients.
Studies find radiation therapy for DCIS does not increase cardiovascular disease risk, while MRI scans may be unnecessary. Additionally, most women have inaccurate perceptions of their personal breast cancer risk, sparking the need for better communication between patients and doctors.
A retrospective study suggests that patients with lung cancer carrying specific HER2 mutations may experience tumor shrinkage and delayed disease progression when treated with anti-HER2 drugs. The study found 1.7% of NSCLC patients in Europe had these rare mutations, which can lead to continuous activation of the HER2 protein.
A Phase III clinical trial found that adding cetuximab to chemotherapy enables previously inoperable patients to undergo surgery, tripling the rates of successful surgery for liver metastasis. The combination also extends median overall survival by 10 months compared to chemotherapy alone.
A large observational follow-up study found that women with lung cancer who consumed more soy food prior to diagnosis lived longer. Soy contains isoflavones that may affect molecular pathways involved in tumor development and growth.
Outpatient oncology practices have seen a significant increase in performance on quality measures, especially in adopting new clinical practices. The mean normalized performance score improved from 71 to 85 percent between 2006 and 2010.
A prospective study found that children with low-risk retinoblastoma do not need postoperative chemotherapy to prevent disease recurrence or metastasis. The results suggest that certain patients with intermediate-risk disease can receive less aggressive adjuvant treatment or even forego it altogether.
Research from the 2013 Genitourinary Cancers Symposium highlights new insights on high-risk prostate cancer prevalence and treatment. Studies show that African-American men and older men of any race are more likely to have aggressive prostate cancer, while surveillance for small kidney tumors is a safe alternative to surgery for elderl...
The 2013 Gastrointestinal Cancers Symposium revealed new advances in treating and prophesizing gastrointestinal cancers. The symposium presented five important studies, including a Phase III clinical trial showing that postoperative treatment with S-1 chemotherapy reduces relapses and extends survival in patients with pancreatic cancer.
The American Society of Clinical Oncology (ASCO) has released its annual report on the top cancer advances of 2012, showcasing significant developments in precision medicine and targeted treatments. The report highlights seven new FDA approvals for anticancer agents, including therapies for breast and prostate cancers.
Several studies presented at the 2012 Quality Care Symposium provide insight into improving quality of cancer care. Researchers found that increasing awareness among physicians and patients can reduce the overuse of diagnostic imaging in young adult cancer survivors, resulting in decreased anxiety and unnecessary radiation exposure.
The American Society of Clinical Oncology's Quality Care Symposium reveals important advances in cancer care quality measurement, physician adherence to quality standards, and end-of-life care. The studies also highlight the overuse of contralateral prophylactic mastectomy.
A study published in the Journal of Clinical Oncology found that earlier end-of-life care discussions are associated with less aggressive care and increased use of hospice care for patients with advanced cancer. Initiating these discussions before the last month of life allows patients to make informed decisions about their care.
The 2012 Breast Cancer Symposium presents four major studies on the treatment of early breast cancer, confirming which patient populations benefit from screening interventions and surgical procedures. The research aims to improve treatment decisions and maximize benefits for patients.
The American Society of Clinical Oncology (ASCO) has released five new studies at its upcoming annual meeting, including those on precision medicine and cancer's genetic weak spots. These studies demonstrate improvements in treatment for aggressive cancers and provide valuable tools to lessen the side effects of cancer treatment.
The study reported a significant increase in five-year and 10-year survival rates for children with acute lymphoblastic leukemia, rising to 90.4% and 83.9%, respectively. Advances in treatment, including new drugs and supportive care, contributed to the improved outcomes.
A study published in the Journal of Clinical Oncology found that women who underwent chemotherapy with the CMF regimen between 1976 and 1995 scored slightly lower on cognitive tests compared to those without a history of cancer. The differences were subtle but statistically significant, affecting word learning, memory, and information ...
A prospective study links Lynch syndrome with significantly increased risks of breast and pancreatic cancers, while relatives without genetic mutations have no increased risk. The study provides clearer estimates of cancer risks associated with Lynch syndrome and may inform screening and early detection strategies.
Research from the 2012 Genitourinary Cancers Symposium highlights promising new therapies for prostate cancer, including vigorous exercise and targeted drugs that improve survival rates. The studies also compare existing treatments, such as radiation therapy and hormone therapy, to determine their effectiveness.
Researchers have made significant progress in detecting and treating gastrointestinal cancers with new biomarkers, test, and treatments. Studies show promising results for detecting early stage pancreatic cancer and improving survival in patients with metastatic colorectal cancer.
A large retrospective study of childhood cancer survivors found no increased risk of birth defects in their children. Researchers examined data from over 20,000 survivors and found that exposure to chemotherapy and radiation did not lead to genetic birth defects.
The American Society of Clinical Oncology (ASCO) has released its annual report on progress against cancer, showcasing the most significant developments in cancer research and policy. The report highlights advances in personalized treatment approaches, early detection, and new drug approvals for various cancers.
A population-based analysis found that close relatives of women with breast cancer who don't carry the BRCA mutation have a similar risk to the general population. The study suggests they may not need extra cancer screening and preventive measures.
A new study found that MRI-assessed tumor responses to neoadjuvant therapy can predict survival among patients with advanced rectal cancer. The findings suggest that using MRI prior to surgery may help change the course of patient care, enabling physicians to choose a more effective chemotherapy drug or avoid surgery in some cases.
New studies released by ASCO highlight advances in cervical cancer screening, ovarian cancer detection, and prostate cancer risk prediction. The studies also explore genetic biomarkers for chemotherapy-induced neuropathy and potential treatments for relapsed ovarian cancer.
A new study found that nearly half of elderly men in their seventies underwent PSA screening, while those aged 85 and older screened just as often as those in their early fifties. The high rate of unnecessary screenings may lead to complications such as incontinence and impotence.
A new study shows that a surgical technique called microdissection testicular sperm extraction (TESE) can effectively locate and extract viable sperm in over one-third of adult male childhood cancer survivors who were previously considered sterile. This technique enabled many men to father children with the help of in vitro fertilization.
New studies reveal a low initial PSA score of 3.0 ng/ml is an appropriate minimum cut-off level for biopsy targeting those at risk, while proficiency in robotic-assisted prostate surgery requires over 1,600 surgeries to master. Dutasteride may also slow early-stage prostate cancer growth.
A novel form of personalized therapy using genetically engineered anti-tumor immune cells shows promising results in treating metastatic melanoma and synovial cell sarcoma. The technique, called adoptive immunotherapy, resulted in response rates of 45% and 67% in malignant melanoma and synovial cell sarcoma patients, respectively.
A new study reveals liver cancer incidence has tripled in the US since 1975, with African-Americans and Hispanics experiencing significant increases. Survival rates have improved significantly, with one-year rates rising from 25% to 47%, thanks to earlier diagnosis and treatment.
A study published in the Journal of Clinical Oncology found that leaving the ovaries intact during surgery for early-stage endometrial cancer has no survival benefit compared to removing them. This approach could spare women from surgery-induced early menopause, hot flashes, and increased risk of heart disease and osteoporosis.
A long-term study found that high insulin-like growth factor binding protein-1 (IGFBP-1) levels reduced overall death risk by over 50%, while high C-peptide levels doubled the risk of death. Lifestyle factors like obesity and physical inactivity are associated with high insulin levels, which can fuel colon cancer growth.
A new study has found an association between past hepatitis B infection and pancreatic cancer. Evidence of past hepatitis B exposure was twice as common in patients with pancreatic cancer compared to healthy controls.
Researchers found that computer models underpredicted BRCA mutation frequency in Asian-American women by 50% compared to Caucasian counterparts. This suggests that more women of Asian descent may be at increased risk of hereditary breast and ovarian cancers than previously believed.
A Swedish study found that more than 40% of widowers were never informed about their wives' incurable cancer or received the news in the last week of her life. The study suggests room for improvement in healthcare provider communication with husbands, particularly those who did not receive information before the wife's death.
Regular mammograms significantly decrease the risk of late-stage breast cancer in women 80 and older, with only about one-fifth receiving them. The study found that each mammogram performed was associated with a further reduction in late-stage disease risk.